tbuckley/cabot-search huggingface dataset:
SURG-15. RESIDENT PARTICIPATION IS NOT ASSOCIATED WITH POSTOPERATIVE ADVERSE EVENTS, REOPERATION, OR PROLONGED LENGTH OF STAY FOLLOWING CRANIOTOMY FOR BRAIN TUMOR RESECTION
Authors: Nikita Lakomkin, Constantinos Hadjipanayis
Journal: Neuro-Oncology (2017)

The impact of the “July effect” on morbidity and mortality rates has been assessed in neurosurgery, but only for heterogeneous cohorts incorporating degenerative spine and diverse cranial operations, including functional cases. The operative resection of brain tumors is characterized by significant surgical complexity, variety, and potentially substantial postoperative morbidity. As such, the purpose of this study was to explore the relationship between resident involvement and patient outcomes following various types of craniotomies for the resection of brain tumors. Data for adult patients undergoing craniotomy for brain tumor resection were extracted from the 2008-2012 National Surgical Quality Improvement database using CPT and ICD-9 coding. Resident involvement was determined for all cases, and evaluated for association with patient outcomes via multivariable, binary logistic regression analysis while controlling for confounding comorbidity and operative variables. Outcomes included death, prolonged length of stay (LOS), readmission, reoperation, neurologic complication, and wound infection. 3,587 cases met inclusion criteria, 2,926 (81.6%) of which involved supratentorial tumors and 661 (18.4%) presenting with infratentorial tumors. Residents participated in 2,281 (63.6%) cases. Resident involvement was associated with a significantly lower risk of prolonged LOS (OR: 0.68, 95%CI: 0.54-0.86, P=0.001). This association was observed for patients undergoing craniotomy for supratentorial tumors (OR: 0.63, 95%CI: 0.49-0.82, P=0.001) but not for infratentorial lesions (OR: 1.05, 95%CI: 0.60-1.84, P=0.86). Resident involvement also approached significance for reduced risk of mortality (OR: 0.63, 95%CI: 0.39-1.03, P=0.06). Resident participation was not an independent predictor of any other outcome metrics for either tumor location. Resident involvement was not a risk factor for any complications or reoperation/readmission, and was associated with reduced risk of prolonged LOS following supratentorial tumor resection. These relationships may be influenced by institutional differences, such as resident participation in the postoperative inpatient care of patients at academic centers.
JCES 01.20 Primary Tumor Resection versus Maintenance Therapy for Patients with Oligometastatic Non-Small Cell Lung Cancer
Authors: X. Kang, H. Zhou, W. Yan, L. Dai, Y. Yang, H. Yang, H. Fu, M. Fan, Y. Lin, Z. Liang, H. Xiong, K. Chen
Journal: Journal of Thoracic Oncology (2017)
GENE-36. ACCURATE DETECTION OF TERT PROMOTER MUTATION IN GLIOMAS USING INFINIUM DNA METHYLATION ARRAYS IDENTIFIES NOVEL EPIGENETIC ASSOCIATION
Authors: Jie Yang, Qianghu Wang, Lihong Long, Ravesanker Ezhilarasan, Erik Sulman
Journal: Neuro-Oncology (2017)

The telomere reverse transcriptase promoter (TERTp) is frequently mutated in malignant gliomas, particularly glioblastomas (GBM, 85%), and is involved in maintaining telomere length. TERTp mutations are prognostic for patient survival. Given the evolving use of Infinium DNA methylation arrays in assaying biomarkers in glioma, we aimed to develop an accurate predictor of TERTp mutations in gliomas using this platform. We analyzed TCGA lower grade glioma (LGG) and GBM available with both TERTp sequencing and Infinium 450k data. Samples were split into training and testing set to determine predictor accuracy. Probes with potential quality issues were excluded and probe selection performed using an elastic net algorithm. Probes were selected across the genome, not limited to the TERTp locus. A logistic regression model with binomial distribution was built using the final optimized model, constructed based on 1000 CpG probes, all distinct from TERTp. Prediction accuracy was 100% (179/179, AUC=1) in the training set and 97.5% (116/119) in the test set. Comparison of the normalized frequency of selected probes by chromosome revealed enrichment for chromosomes 20 (0.4987%) and 18 (0.4859%). The majority of probes enriched in CpG islands (53.6%), followed by open sea (22.9%), shore (17.4%), and shelf (6.1%). Relative to known genes, probe enrichment occurred predominantly near transcriptional start sites (within 200–1500 bp, 31.0%), followed by gene bodies (26.3%) and intergenic regions (18.3%). Quite unexpectedly, probes within the predictor do not map near TERT or other telomere maintenance factors nor fell within known methylation signatures, such as G-CIMP, suggesting that TERTp mutation is associated with novel epigenetic changes. Moreover, this biomarker permits rapid and cost effective detection of TERTp mutation using the widely used Infinium platform.
P1.01-059 Combination Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel for Patients with Recurrent/Metastatic NSCLC and PS of 2
Authors: T. Ahmed, P. Triozzi, S. Addo, M. Kooski, W. Petty, J. Ruiz, S. Grant, R. D'Agostino, M. Bonomi
Journal: Journal of Thoracic Oncology (2017)
Carta a la redacción: Brotes de parvovirus B19
Authors: B J Cohen
Journal: Eurosurveillance (2005)

In response to the recent report of school outbreaks of parvovirus B19 infection in Portugal [1], Heath Kelly and Jennie Leydon of the Western Pacific Regional Measles Laboratory, have echoed the call for parvovirus B19 tests to be included in measles and rubella surveillance.
Investigación de un brote de tuberculosis en una agencia de empleo, Manchester, Reino-Unido
Authors: A Kirkpatrick, C Bell, M Petrovic, M Woodhead, A Barrett, E Duffell, A Verma, F Reynolds
Journal: Eurosurveillance (2006)

Durante el verano de 2005, se investigaron cuatro casos de tuberculosis activa procedentes del mismo lugar de trabajo en Manchester, en el Reino-Unido. El caso indice se habia diagnosticado en diciembre del ano precedente. En ese tiempo, el estudio de los contactos profesionales mas cercanos habia confirmado que todos estaban libres de la enfermedad. Ademas, ninguno necesito quimioprofilaxis para la infeccion tuberculosa latente (ITBL), segun los criterios recomendados al nivel nacional. 
En junio de 2005, dos contactos profesionales desarrollaron una TB extrapulmonar progresiva primaria (pleural). Tras una evaluacion detallada del riesgo, el programa de cribado se amplio para incluir a 137 empleados de la oficina donde se habian identificado los cuatro primeros casos. El programa de cribado se basaba en la realizacion de la prueba de Mantoux (sensibilidad a la tuberculina), Rx de torax y la prueba de gamma-interferon. Entre las 137 personas estudiadas, se detecto enfermedad activa en una y se ofrecio quimioprofilaxis a otras seis con ITBL. Los aislamientos del caso indice y de los dos primeros casos secundarios eran indistinguibles con el metodo MIRU-VNTR (mycobacterial interspersed repetitive unit-variable-number tandem repeat) con un tipado de 15 loci. No habia disponibles muestras del cuarto caso de tuberculosis activa.
La gestion de este brote se beneficio de los progresos de las tecnicas de genotipado y de las pruebas diagnosticas del ITBL. Sin embargo, se necesita investigar mas acerca de las implicaciones epidemiologicas del genotipado. Tambien hay que estudiar el significado de una prueba interferon gamma positiva para evaluar el riesgo de desarrollar una tuberculosis activa.
Abstract #5135: Down-regulation of HDGF induces apoptosis in human cancer cells through the Fas-mediated extrinsic apoptotic pathway
Authors: Tsun Yee Tsang, Wan Yee Tang, Wing Pui Tsang, Ngai Na Co, Au Yeung Chi Lam, Tim Tak Kwok
Journal: Cancer Research (2009)

Hepatoma-derived growth factor (HDGF) is shown to be overexpressed in different types of human cancers. Although the growth factor is found to promote cancer development and progression, information about the mechanisms is however limited. The aim of the present study is to examine the role of HDGF in the growth of human cancer cells and the underlying mechanisms. By MTT assay and soft agar assay, knock-down of HDGF by transfection with HDGF specific antisense oligonucleotides was found to suppress the anchorage-dependent and anchorage-independent growth of human hepatocellular carcinoma HepG2 cells. Moreover, knock-down of HDGF also induced apoptosis in HepG2 cells as determined by both DNA fragmentation assay and annexin V binding assay. Similar results were shown in other human cancer cells, including hepatocellular carcinoma Hep3B cells, human squamous cell carcinoma A431 cells, human cervical carcinoma CaSki cells and SiHa cells. By the use of Western blot analysis, the expression level of pro-apoptotic protein Fas was found to be up-regulated in cells after knock-down of HDGF. At the same time, the cells also demonstrated increases in the cleavages of caspase-8 and -3. Knock-down of Fas using Fas specific siRNA or using caspase-8 and caspase-3 specific inhibitors can both reduce the level of apoptosis induction upon HDGF knock-down. The results from the present study therefore suggested that HDGF may be essential for the survival of cancer cells. Knock-down of HDGF can lead to apoptotic cell death in human cancer cells through the activation of the Fas-mediated extrinsic apoptotic pathway.   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5135.
MA 16.12 Prolonged Survival after Pulmonary Metastasectomy for Testicular Germ-cell Tumors in a Single Institution
Authors: J. Corona-Cruz, G. Mirando-Devora, J. González Luna, M. Alvarez-Avitia, J. Martinez-Cedillo, R. López Saucedo, O. Arrieta
Journal: Journal of Thoracic Oncology (2017)
Erratum: Corrigendum: Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation
Authors: Marie Toussaint, David J Jackson, Dawid Swieboda, Anabel Guedán, Theodora-Dorita Tsourouktsoglou, Yee Man Ching, Coraline Radermecker, Heidi Makrinioti, Julia Aniscenko, Michael R Edwards, Roberto Solari, Frédéric Farnir, Venizelos Papayannopoulos, Fabrice Bureau, Thomas Marichal, Sebastian L Johnston
Journal: Nature Medicine (2017)
CSIG-35. A LOCALLY TRANSLATED Lck PATHWAY REGULATES HUMAN GLIOMA CELL MIGRATION, TUMOR GROWTH AND STEMNESS GENE EXPRESSION
Authors: John Zepecki, Kristin Snyder, Steven Toms, Atom Sarkar, Nikos Tapinos
Journal: Neuro-Oncology (2017)

Migration of human glioma stem cells (hGSCs) within the brain parenchyma makes glioblastoma one of the most aggressive and lethal tumors. Studies of the cellular and molecular mechanisms underlying hGSC migration are hindered by the limitations of existing migration models. Here we developed a dorsal root ganglion axon-oligodendrocyte-hGSC co-culture to study in real time the migration and interaction of hGSCs with their microenvironment. hGSCs interact with myelinated and non-myelinated axons through the formation of pseudopodia. Isolation of pseudopodia-localized polysome-bound RNA reveals transcripts of LCK, PAXILLIN, CRK-II and RAC1 that undergo local translation. Inhibition of Lck blocks the activation of this pathway, the formation of pseudopodia and the migration of hGSCs. In vivo intraventricular administration of a highly specific small-molecule inhibitor of Lck using an orthotopic xenograft mouse model results in significant inhibition of tumor growth and significant down-regulation of stemness gene expression. Targeting this Lck pathway constitutes a novel treatment paradigm for human glioblastomas.
P1.16-026 Multimodal Image-Guided VATS Resection of Sub-Centimeter Pulmonary Nodules by Cone Beam CT and Bronchoscopic NIR Fluorescence Marking
Authors: T. Anayama, K. Hirohashi, H. Okada, N. Kawamoto, R. Miyazaki, M. Yamamoto, M. Kume, K. Orihashi
Journal: Journal of Thoracic Oncology (2017)
CBIO-30. TUMOR TREATING FIELDS (TTFIELDS) INHIBIT CANCER CELL MIGRATION AND INVASION BY INDUCING REORGANIZING OF THE ACTIN CYTOSKELETON AND FORMATION OF CELL ADHESIONS
Authors: Rosa Schneiderman, Einav Zeevi, Tali Voloshin, Anna Shteingauz, Moshe Giladi, Yaara Porat, Mijal Munster, Eilon D Kirson, Uri Weinberg, Yoram Palti
Journal: Neuro-Oncology (2017)

TTFields have been demonstrated to disrupt cancer cell replication in cultures, inhibit tumor progression in animals and increase overall survival in GBM patients when combined with temozolomide. TTFields are delivered via continuous, noninvasive application of low intensity, intermediate frequency alternating electric fields. In this study we have investigated TTFields effect on cancer cell migration and invasion properties. Glioma, breast, colon, melanoma and NSCLC cancer cell lines were treated with TTFields using the inovitro and the inovitro live systems. Cell migration rates were measured using wound healing assays. Invasion assays were performed using a modified Matrigel coated Boyden chamber. Cell adhesion assays were performed during TTFields treatment and compared to untreated controls. At the end of TTFields’ treatment, adhered cells were trypsinized and counted. A cells de-adhesion assay was performed following different durations of TTFields application with the outcome being the number of cells removed after varying times of trypsinization. Confocal fluorescence microscopy imaging of vinculin and F-actin were utilized to demonstrate changes in cellular focal adhesions and stress fibers following TTFields application, respectively. Application of TTFields in-vitro led to a significant reduction in cell migration velocity compared with untreated control cells. Cancer cells invasion was significantly reduced compared to untreated cells in all tested cell lines. In addition, cell de-adherence following TTFields treatment took significantly longer time of trypsinization. TTFields application also resulted in an increase in focal adhesion size and number as well as peripheral distribution of the adhesion sites. TTFields treated cells also adopted a more flattened and spread shape and exhibit reduction in appearance of stress fibers and a dense meshwork of actin filaments around the entire cell periphery. While typically regarded as an anti-mitotic treatment modality, TTFields may warrant further investigation and development for their anti-invasive and anti-metastatic potential.
P3.02-053 Optimization and Characterization of Assays to Identify Met Exon 14 Skipping in FFPE Embedded NSCLC Samples
Authors: S. Gray, O. O’Brien, C. O'Brien, M. Wright, O. Geoghegan, N. Leonard, S. Nicholson, J. Wolfram, M. Joerger, A. Fabre, S. Cuffe, S. Finn
Journal: Journal of Thoracic Oncology (2017)
IDH mutant and 1p19q codeleted low grade gliomas: to treat or not to treat?
Authors: A. Tosoni, E. Franceschi, A. Mura, S. Minichillo, A. Pession, D. De Biase, D. Danieli, S. Pizzolitto, A. Fioravanti, L. Volpin, R. Agati, G. Genestreti, R. Degli Esposti, S. Bartolini, A. Paccapelo, A.A. Brandes
Journal: Annals of Oncology (2017)
ACTR-03. INDUCING FACTORS OF MALIGNANT RECURRENCE IN LOW-GRADE GLIOMA
Authors: Soko Ikuta, Takashi Maruyama, Masayuki Nitta, Saori Okamoto, Yasukazu Fukuya, Takayuki Yasuda, Takashi Komori, Takakazu Kawamata, Yoshihiro Muragaki
Journal: Neuro-Oncology (2017)

Low-grade glioma patients have relatively long life expectancy for gliomas, but once they recur in malign, their prognosis can be poor. We analyzed factors corresponding to malignant recurrence by uni- and multi-variate analysis applying their treatment backgrounds. SUBJECTS: 261 newly diagnosed WHO grade 2 adults gliomas in 2004 to 2014. Malignant recurrence was determined by pathological diagnosis if the patient had a surgery (69% of the recurrent patients), otherwise contrast T1WI or 11C- methionine PET images if the patient was unable to undergo any surgery or biopsy. Age average 41 years old, the 10-year survival rate in all patients was 75%, and the mean of progression-free survival time was 7.8 years. Relapse event occurred in 115 cases (44%), and 67 % of them developed malignant glioma sometime. The 10-year survival rate for the patients who relapsed in malign was 37%, on the contrary, the patients who had recurrence but staying in low grade was 71% (p=0.0389). When they were categorized by 1p19q deletion and IDH1 mutation status, IDH wild type diffuse astrocytoma patients had significantly developed malignant glioma compared to oligodendroglioma and IDH mutant type diffuse astrocytoma (p<0.0001). The factors related to malignant progression were extracted as; recurrence in 2 years, 6% and over in MIB-1 index, no intervention longer than 18 months since the disease revealed, 1p19q non-co-deletion, less than 90% of tumor resection rate, and IDH wild type. In the 1p19q non-deletion patients, who were provisionally defined as diffuse astrocytoma patients here, the factors were resection rate, MIB-1 index, and duration between discovered the disease and the first surgery, but not the IDH mutant status (p＜0.0001, p=0.0015, p=0.0478 respectively). Recurrence in malign form low-grade glioma can be avoided by early intervention in 18 months from diagnosis and resection over 90% of volume of the tumor.
Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).
Authors: Jean-Charles Soria, John H. Strickler, Ramaswamy Govindan, Seungjean Chai, Nancy Chan, Vanesa Quiroga-Garcia, Rastislav Bahleda, Cinta Hierro, Bob Zhong, Martha Gonzalez, Ademi E. Santiago-Walker, Trilok V. Parekh, Feng Roger Luo, Loretta Sullivan-Chang, Hong Xie, Josep Tabernero
Journal: Journal of Clinical Oncology (2017)

4074 Background: Erdafitinib (JNJ-42756493) is a potent, oral pan-FGFR tyrosine kinase inhibitor that demonstrated encouraging preliminary clinical activity and manageable adverse events (AEs) in its first-in-human phase 1 study in advanced solid tumors (NCT01703481). Here we report results from pts with CCA from this study. Methods: This 4-part study enrolled pts age ≥ 18 years (y) with advanced solid tumors. Dose escalation (part 1) followed a 3+3 design, with pts receiving ascending doses of erdafitinib continuously or intermittently (7 days on/7 days off). Subsequent parts required FGFR gene alterations in the tumor, including activating mutations and translocations or other FGFR-activating aberrations. Part 2 was a pharmacodynamics cohort. Parts 3 and 4 were dose-expansion cohorts for recommended phase 2 doses of 9 mg once daily (QD) and 10 mg intermittently, respectively. Results: Eleven pts with FGFR-aberrant CCA were treated at 9 mg QD (n = 1) or 10 mg intermittent (n = 10). Median age was 60 y; 7 of 11 pts were female (64%). 73% of pts had ECOG performance status 1. All had prior systemic therapy. Median treatment duration with erdafitinib was 5.3 months (mo). Systemic erdafitinib exposure, per C max and AUC, in CCA pts was similar to other indications. The most common AEs were stomatitis (82%), hyperphosphatemia (64%), dry mouth (55%), dysgeusia (45%), dry skin (45%), and asthenia (45%), mostly grade 1/2 severity. No drug-related grade ≥3 AEs were reported in &gt; 1 pt except grade 3 stomatitis (n = 2; 18%). The objective response rate, all confirmed partial responses (PRs) per RECIST 1.1, was 27.3% (3/11; 95% CI 6, 61); an additional 27.3% (3/11) had stable disease as their best response. Overall disease control rate was 55%. All 3 PRs were at the 10 mg intermittent dosage, and the median duration of response was 12.9 mo. With a median follow-up of 5.1 mo, median progression-free survival was 5.1 mo (95% CI 1.6, 16.4). As of the cutoff date, 2 pts continue on study treatment. Conclusions: Erdafitinib showed encouraging clinical activity and minimal toxicity in pts with advanced CCA and FGFR alterations. These results warrant further study. Clinical trial information: NCT01703481.
Tatuaje y piercing – la necesidad de recomendaciones europeas
Authors: N Noah
Journal: Eurosurveillance (2006)

Tal y como sucedio en Amsterdam [1], un brote de hepatitis B producido en 1978 debido a una persona que realizaba tatuajes fue la ocasion de elaborar recomendaciones de higiene para la practica del tatuaje en el Reino Unido. Durante este brote se identificaron 30 casos primarios y tres secundarios [2]. Al poco tiempo, se elaboraron recomendaciones para un tatuaje higienico, que en general fueron bien acogidas por el sector. Estas recomendaciones se extendieron en 1982 a la acupuntura, el piercing de oreja y la depilacion por electrolisis. Al mismo tiempo, se votaron las leyes sobre el control de higiene de los que practican estas tecnicas {Local Government Miscellaneous Provisions Act 1982 [modificado en 2003] y el Greater London Council [General Powers] Act 1982}. El piercing corporal no se conocia mucho en esa epoca, aunque sin duda existia y se practicaba furtivamente. Siguieron otras recomendaciones para las terapias esteticas, la higiene de la peluqueria y la micropigmentacion.
CSIG-30. CHARACTERIZING THE OVER-EXPRESSION OF Yki/YAP/TAZ TRANSCRIPTION FACTORS IN GLIOMAGENESIS AND A PROPOSED NOVEL TREATMENT OF GLIOBLASTOMAS
Authors: Krishanthan Vigneswaran, Se-Yeong Oh, Zhaobin Zhang, Jeffrey J Olson, Renee Read
Journal: Neuro-Oncology (2017)

Glioblastomas (GBMs) are among the most common primary malignant brain tumors in adults and are resistant to current therapies. The most frequent genetic lesions in GBMs include amplification, mutation, and/or over expression of receptor tyrosine kinases (RTKs) and mutations that constitutively activate the PI-3 kinase (PI3K) pathway. Using a novel RNAi screen in a Drosophila model of RTK-driven glioblastoma, our lab has previously reported conserved kinase pathways required for tumor growth. We have recently focused on the Hippo kinase pathway and it downstream targets, the Yki-YAP/TAZ transcription factors, which normally control stem/progenitor cell proliferation and self-renewal in several tissues. Our preliminary data reveal that YAP and TAZ become overexpressed in tumor cells with RTK amplification or mutation, and that YAP/TAZ drive GBM cell proliferation and survival. We hypothesize that, as a consequence of RTK activity, YAP and/or TAZ become overexpressed and activated to constitutively drive a transcriptional program that provokes an uncontrolled expansion of mutant neural stem/progenitor cells to create malignant glial tumors. YAP and/or TAZ promote the initiation and progression of other tumor types and several published studies show that pharmacologic inhibition of YAP and TAZ blocks tumor cell growth in vitro and in animal models. In testing this hypothesis, we have generated data that demonstrates that pharmacologic inhibition of YAP and TAZ specifically elicits growth arrest and apoptosis in GBM cells, and rapidly alters the expression of transcriptional target genes required for tumor cell survival in GBM cells. We are now testing the therapeutic potential of YAP/TAZ inhibition in GBMs driven by RTK mutations.
P3.13-018 CT-Guided Percutaneous Barium Marking Prior to Video-Assisted Thoracoscopic Surgery (VATS) for the Localization of Small Pulmonary Nodules
Authors: A. Gelatti, F. Martins, R. Piccoli, V.K. Gonçalves, V. Lorandi, T. Da Silva, M. Pasa, R. Bello, C. Barrios
Journal: Journal of Thoracic Oncology (2017)